PAREXEL, an innovator of global biopharmaceutical services, introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.
PAREXEL Biotech combines the company’s expertise and global infrastructure with a model that is aligned to this specific segment, providing enhanced consulting and development capabilities through a new biotech-focused team and organizational structure. This team led by James Anthony and Graciela Racaro, will help emerging companies minimize complexity, reduce costs, and accelerate timelines through the use of many different strategies and services. Those services and strategies include global regulatory consulting, patient recruitment services, trial execution services, Real World Evidence programs, and much more.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.